Article

Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal Intervention

2026-03-25

Abstract excerpt

<h4>Background: </h4> Androgen deprivation therapy (ADT) is widely used in the management of prostate cancer (PCa) and remains a cornerstone of treatment across multiple disease settings. Although ADT con-tributes substantially to disease control, it also induces significant adverse metabolic and body composition changes. These alterations include loss of lean mass, increased fat mass, and deterio-ration in muscle...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6df0ac63-000a-5a85-8e90-ae277aee87b9
DOI: 10.20944/preprints202603.1954.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal InterventionDOI 10.20944/preprints202603.1954.v1Read

Appraising causal relationships of dietary, nutritional and physical-activity exposures with overall and aggressive prostate cancer: two-sample Mendelian-randomization study based on 79 148 prostate-cancer cases and 61 106 controlsSemantic proximity Read

Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer.Semantic proximity Read

Aerobic physical exercise enhances nanoparticle efficacy in prostate cancer treatmentSemantic proximity Read

Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer riskSemantic proximity Read

Lipedema and Dynapenia: Inflammatory Myosteatosis as a Mechanistic Link Between Tissue Expansion and Muscle DysfunctionSemantic proximity Read

PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal.Semantic proximity Read

Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping.Semantic proximity Read

Serum lncRNAs NEAT1, PVT1 and H19 as novel biomarkers for sarcopenia diagnosis and treatment responseSemantic proximity Read

Myopenia and precision (P4) medicineSemantic proximity Read

Treatment of body composition changes in obese and overweight older adults: insight into the phenotype of sarcopenic obesity.Semantic proximity Read

Exercise Interventions for the Management of Sarcopenia: Possibilities and ChallengesSemantic proximity Read

Which are the long-term outcomes of prostate cancer patients undergoing non-interventional management (i.e., watchful waiting) and what is the impact of comorbidities and life expectancy? – PIONEER Research Question #2Semantic proximity Read